Drug Trial Radar · NCT05255484
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Oct 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
May 26, 2022
Primary completion
Oct 6, 2023
Study completion Oct 6, 2023
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
Interventions
LM-108Drug
Administered intravenously
An Anti-PD-1 AntibodyDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEsTime frame: 126 weeks
- DLTTime frame: 21 days
- SAETime frame: 126 weeks
- Incidence of clinical significant in laboratory examinationsTime frame: 126 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Ocala Oncology Center
Ocala, Florida
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
Gabrail Cancer and Research Center
Canton, Ohio
The Christ Hospital
Cincinnati, Ohio
University of Oklahoma
Norman, Oklahoma
Mary Crowley Cancer Research
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.